Literature DB >> 32240772

Outcomes after Cholecystectomy in Patients with Sickle Cell Disease: Does Acuity of Presentation Play a Role?

Asa Ramdath1, Ahmad Zeineddin2, Wasay Nizam2, LaDonna Kearse2, Olubode A Olufajo3, Mallory Williams2.   

Abstract

BACKGROUND: Cholecystectomy is the most commonly performed procedure in sickle cell disease (SCD) patients, but outcomes after cholecystectomy have not been well studied. Our aim was to explore the characteristics and outcomes of cholecystectomy in patients with SCD compared with patients without SCD, and assess whether acuity of presentation played a role. STUDY
DESIGN: Patients younger than age 35, with the primary diagnosis of gallbladder disease, who underwent cholecystectomy, were identified in the Nationwide Inpatient Sample (2005 to 2014). Patients were grouped into treatment groups by sickle cell status and acuity of surgery. Patient demographics, length of stay, hospital charges, and complications were evaluated. Descriptive and multivariate regression analyses were performed to compare these groups.
RESULTS: There were 149,415 patients analyzed; 1,225 (0.82%) had SCD. SCD was associated with higher complication rates (2.69% vs 1.12%), longer lengths of stay (3 days vs 2 days), and higher median hospital charge ($29,170 vs $25,438) (all p < 0.01). Stratified by level of acuity, comparing the SCD group with the non-SCD group, higher complication rates were seen in the acute presentation group (3.92% vs 1.00%, p < 0.01), but were not demonstrated in the elective group (0.98% vs 1.95%, p = 0.114).
CONCLUSIONS: SCD patients appear to have a longer length of stay, higher hospital spending, and increased complication rates compared with non-SCD patients undergoing cholecystectomy. This difference is pronounced among patients who underwent surgery in the acute setting. The data suggest that planned cholecystectomy may be beneficial in improving postoperative outcomes in SCD patients.
Copyright © 2020 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32240772     DOI: 10.1016/j.jamcollsurg.2020.02.046

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  2 in total

1.  Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis.

Authors:  Zachary Baldwin; Boshen Jiao; Anirban Basu; Joshua Roth; M A Bender; Zizi Elsisi; Kate M Johnson; Emma Cousin; Scott D Ramsey; Beth Devine
Journal:  Pharmacoecon Open       Date:  2022-04-26

2.  Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S.

Authors:  Arianna Barbetta; Cameron Goldbeck; Angelina Lim; Sean P Martin; Jeffrey A Kahn; M Raashid Sheikh; Juliet Emamaullee
Journal:  HPB (Oxford)       Date:  2021-07-06       Impact factor: 3.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.